sales@reportocean.com (Bussiness Sales)
+18882123539 (Us - Toll Free)
+919997112116 (Rest Of World)
Global Antibody Therapeutics Market Size study, by Format, by Route of Administration, by Source, by Disease Areas, by End User and Regional Forecasts 2024-2032

Global Antibody Therapeutics Market Size study, by Format, by Route...

Home / Categories / Healthcare
Global Antibody Therapeutics Market Size study, by Format, by Route of Administration, by Source, by Disease Areas, by End User and Regional Forecasts 2024-2032
Global Antibody Therapeutics Market Size...
Report Code
RO1/103/2901

Publish Date
30/Aug/2024

Pages
200
PRICE
$ 1800/-
This is a single user license, allowing one specific user access to the product. The product is a PDF.
$ 2350/-
This is a 1-5 user license, allowing up to five users have access to the product. The product is a PDF.
$ 2850/-
This is an enterprise license, allowing all employees within your organization access to the product. The product is a PDF..
Table of Contents
Chapter 1. Global Antibody Therapeutics Market Executive Summary
1.1. Global Antibody Therapeutics Market Size & Forecast (2022- 2032)
1.2. Regional Summary
1.3. Segmental Summary
1.3.1. By Format
1.3.2. By Route of Administration
1.3.3. By Source
1.3.4. By Disease Areas
1.3.5. By End User
1.4. Key Trends
1.5. Recession Impact
1.6. Analyst Recommendation & Conclusion
Chapter 2. Global Antibody Therapeutics Market Definition and Research Assumptions
2.1. Research Objective
2.2. Market Definition
2.3. Research Assumptions
2.3.1. Inclusion & Exclusion
2.3.2. Limitations
2.3.3. Supply Side Analysis
2.3.3.1. Availability
2.3.3.2. Infrastructure
2.3.3.3. Regulatory Environment
2.3.3.4. Market Competition
2.3.3.5. Economic Viability (Consumer's Perspective)
2.3.4. Demand Side Analysis
2.3.4.1. Regulatory frameworks
2.3.4.2. Technological Advancements
2.3.4.3. Environmental Considerations
2.3.4.4. Consumer Awareness & Acceptance
2.4. Estimation Methodology
2.5. Years Considered for the Study
2.6. Currency Conversion Rates
Chapter 3. Global Antibody Therapeutics Market Dynamics
3.1. Market Drivers
3.1.1. Increasing Prevalence of Chronic Diseases
3.1.2. Advancements in Medical Technology
3.2. Market Challenges
3.2.1. High Development Costs
3.2.2. Complex Regulatory Approvals
3.3. Market Opportunities
3.3.1. Emergence of Next-Generation Antibodies
3.3.2. Supportive Government Initiatives for Cancer Care
Chapter 4. Global Antibody Therapeutics Market Industry Analysis
4.1. Porter's 5 Force Model
4.1.1. Bargaining Power of Suppliers
4.1.2. Bargaining Power of Buyers
4.1.3. Threat of New Entrants
4.1.4. Threat of Substitutes
4.1.5. Competitive Rivalry
4.1.6. Futuristic Approach to Porter's 5 Force Model
4.1.7. Porter's 5 Force Impact Analysis
4.2. PESTEL Analysis
4.2.1. Political
4.2.2. Economical
4.2.3. Social
4.2.4. Technological
4.2.5. Environmental
4.2.6. Legal
4.3. Top investment opportunity
4.4. Top winning strategies
4.5. Disruptive Trends
4.6. Industry Expert Perspective
4.7. Analyst Recommendation & Conclusion
Chapter 5. Global Antibody Therapeutics Market Size & Forecasts by Format 2022-2032
5.1. Segment Dashboard
5.2. Global Antibody Therapeutics Market: Format Revenue Trend Analysis, 2022 & 2032 (USD Billion)
5.2.1. Antibody Fragment
5.2.2. Bispecific Antibody
5.2.3. Monoclonal Antibody
5.2.4. Polyclonal Antibody
Chapter 6. Global Antibody Therapeutics Market Size & Forecasts by Route of Administration 2022-2032
6.1. Segment Dashboard
6.2. Global Antibody Therapeutics Market: Route of Administration Revenue Trend Analysis, 2022 & 2032 (USD Billion)
6.2.1. Intravenous
6.2.2. Subcutaneous
Chapter 7. Global Antibody Therapeutics Market Size & Forecasts by Source 2022-2032
7.1. Segment Dashboard
7.2. Global Antibody Therapeutics Market: Source Revenue Trend Analysis, 2022 & 2032 (USD Billion)
7.2.1. Chimeric
7.2.2. Human
7.2.3. Humanized
Chapter 8. Global Antibody Therapeutics Market Size & Forecasts by Disease Areas 2022-2032
8.1. Segment Dashboard
8.2. Global Antibody Therapeutics Market: Disease Areas Revenue Trend Analysis, 2022 & 2032 (USD Billion)
8.2.1. Autoimmune & Inflammatory Diseases
8.2.2. Hematology
8.2.3. Immunology
8.2.4. Neurology
8.2.5. Oncology
8.2.6. Osteology
Chapter 9. Global Antibody Therapeutics Market Size & Forecasts by End User 2022-2032
9.1. Segment Dashboard
9.2. Global Antibody Therapeutics Market: End User Revenue Trend Analysis, 2022 & 2032 (USD Billion)
9.2.1. Hospitals
9.2.2. Long-term Care Facilities
Chapter 10. Global Antibody Therapeutics Market Size & Forecasts by Region 2022-2032
10.1. North America Antibody Therapeutics Market
10.1.1. U.S. Antibody Therapeutics Market
10.1.1.1. Format breakdown size & forecasts, 2022-2032
10.1.1.2. Route of Administration breakdown size & forecasts, 2022-2032
10.1.1.3. Source breakdown size & forecasts, 2022-2032
10.1.1.4. Disease Areas breakdown size & forecasts, 2022-2032
10.1.1.5. End User breakdown size & forecasts, 2022-2032
10.1.2. Canada Antibody Therapeutics Market
10.1.2.1. Format breakdown size & forecasts, 2022-2032
10.1.2.2. Route of Administration breakdown size & forecasts, 2022-2032
10.1.2.3. Source breakdown size & forecasts, 2022-2032
10.1.2.4. Disease Areas breakdown size & forecasts, 2022-2032
10.1.2.5. End User breakdown size & forecasts, 2022-2032
10.2. Europe Antibody Therapeutics Market
10.2.1. UK Antibody Therapeutics Market
10.2.1.1. Format breakdown size & forecasts, 2022-2032
10.2.1.2. Route of Administration breakdown size & forecasts, 2022-2032
10.2.1.3. Source breakdown size & forecasts, 2022-2032
10.2.1.4. Disease Areas breakdown size & forecasts, 2022-2032
10.2.1.5. End User breakdown size & forecasts, 2022-2032
10.2.2. Germany Antibody Therapeutics Market
10.2.2.1. Format breakdown size & forecasts, 2022-2032
10.2.2.2. Route of Administration breakdown size & forecasts, 2022-2032
10.2.2.3. Source breakdown size & forecasts, 2022-2032
10.2.2.4. Disease Areas breakdown size & forecasts, 2022-2032
10.2.2.5. End User breakdown size & forecasts, 2022-2032
10.2.3. France Antibody Therapeutics Market
10.2.3.1. Format breakdown size & forecasts, 2022-2032
10.2.3.2. Route of Administration breakdown size & forecasts, 2022-2032
10.2.3.3. Source breakdown size & forecasts, 2022-2032
10.2.3.4. Disease Areas breakdown size & forecasts, 2022-2032
10.2.3.5. End User breakdown size & forecasts, 2022-2032
10.2.4. Spain Antibody Therapeutics Market
10.2.4.1. Format breakdown size & forecasts, 2022-2032
10.2.4.2. Route of Administration breakdown size & forecasts, 2022-2032
10.2.4.3. Source breakdown size & forecasts, 2022-2032
10.2.4.4. Disease Areas breakdown size & forecasts, 2022-2032
10.2.4.5. End User breakdown size & forecasts, 2022-2032
10.2.5. Italy Antibody Therapeutics Market
10.2.5.1. Format breakdown size & forecasts, 2022-2032
10.2.5.2. Route of Administration breakdown size & forecasts, 2022-2032
10.2.5.3. Source breakdown size & forecasts, 2022-2032
10.2.5.4. Disease Areas breakdown size & forecasts, 2022-2032
10.2.5.5. End User breakdown size & forecasts, 2022-2032
10.2.6. Rest of Europe Antibody Therapeutics Market
10.2.6.1. Format breakdown size & forecasts, 2022-2032
10.2.6.2. Route of Administration breakdown size & forecasts, 2022-2032
10.2.6.3. Source breakdown size & forecasts, 2022-2032
10.2.6.4. Disease Areas breakdown size & forecasts, 2022-2032
10.2.6.5. End User breakdown size & forecasts, 2022-2032
10.3. Asia-Pacific Antibody Therapeutics Market
10.3.1. China Antibody Therapeutics Market
10.3.1.1. Format breakdown size & forecasts, 2022-2032
10.3.1.2. Route of Administration breakdown size & forecasts, 2022-2032
10.3.1.3. Source breakdown size & forecasts, 2022-2032
10.3.1.4. Disease Areas breakdown size & forecasts, 2022-2032
10.3.1.5. End User breakdown size & forecasts, 2022-2032
10.3.2. India Antibody Therapeutics Market
10.3.2.1. Format breakdown size & forecasts, 2022-2032
10.3.2.2. Route of Administration breakdown size & forecasts, 2022-2032
10.3.2.3. Source breakdown size & forecasts, 2022-2032
10.3.2.4. Disease Areas breakdown size & forecasts, 2022-2032
10.3.2.5. End User breakdown size & forecasts, 2022-2032
10.3.3. Japan Antibody Therapeutics Market
10.3.3.1. Format breakdown size & forecasts, 2022-2032
10.3.3.2. Route of Administration breakdown size & forecasts, 2022-2032
10.3.3.3. Source breakdown size & forecasts, 2022-2032
10.3.3.4. Disease Areas breakdown size & forecasts, 2022-2032
10.3.3.5. End User breakdown size & forecasts, 2022-2032
10.3.4. Australia Antibody Therapeutics Market
10.3.4.1. Format breakdown size & forecasts, 2022-2032
10.3.4.2. Route of Administration breakdown size & forecasts, 2022-2032
10.3.4.3. Source breakdown size & forecasts, 2022-2032
10.3.4.4. Disease Areas breakdown size & forecasts, 2022-2032
10.3.4.5. End User breakdown size & forecasts, 2022-2032
10.3.5. South Korea Antibody Therapeutics Market
10.3.5.1. Format breakdown size & forecasts, 2022-2032
10.3.5.2. Route of Administration breakdown size & forecasts, 2022-2032
10.3.5.3. Source breakdown size & forecasts, 2022-2032
10.3.5.4. Disease Areas breakdown size & forecasts, 2022-2032
10.3.5.5. End User breakdown size & forecasts, 2022-2032
10.3.6. Rest of Asia Pacific Antibody Therapeutics Market
10.3.6.1. Format breakdown size & forecasts, 2022-2032
10.3.6.2. Route of Administration breakdown size & forecasts, 2022-2032
10.3.6.3. Source breakdown size & forecasts, 2022-2032
10.3.6.4. Disease Areas breakdown size & forecasts, 2022-2032
10.3.6.5. End User breakdown size & forecasts, 2022-2032
10.4. Latin America Antibody Therapeutics Market
10.4.1. Brazil Antibody Therapeutics Market
10.4.1.1. Format breakdown size & forecasts, 2022-2032
10.4.1.2. Route of Administration breakdown size & forecasts, 2022-2032
10.4.1.3. Source breakdown size & forecasts, 2022-2032
10.4.1.4. Disease Areas breakdown size & forecasts, 2022-2032
10.4.1.5. End User breakdown size & forecasts, 2022-2032
10.4.2. Mexico Antibody Therapeutics Market
10.4.2.1. Format breakdown size & forecasts, 2022-2032
10.4.2.2. Route of Administration breakdown size & forecasts, 2022-2032
10.4.2.3. Source breakdown size & forecasts, 2022-2032
10.4.2.4. Disease Areas breakdown size & forecasts, 2022-2032
10.4.2.5. End User breakdown size & forecasts, 2022-2032
10.4.3. Rest of Latin America Antibody Therapeutics Market
10.4.3.1. Format breakdown size & forecasts, 2022-2032
10.4.3.2. Route of Administration breakdown size & forecasts, 2022-2032
10.4.3.3. Source breakdown size & forecasts, 2022-2032
10.4.3.4. Disease Areas breakdown size & forecasts, 2022-2032
10.4.3.5. End User breakdown size & forecasts, 2022-2032
10.5. Middle East & Africa Antibody Therapeutics Market
10.5.1. Saudi Arabia Antibody Therapeutics Market
10.5.1.1. Format breakdown size & forecasts, 2022-2032
10.5.1.2. Route of Administration breakdown size & forecasts, 2022-2032
10.5.1.3. Source breakdown size & forecasts, 2022-2032
10.5.1.4. Disease Areas breakdown size & forecasts, 2022-2032
10.5.1.5. End User breakdown size & forecasts, 2022-2032
10.5.2. South Africa Antibody Therapeutics Market
10.5.2.1. Format breakdown size & forecasts, 2022-2032
10.5.2.2. Route of Administration breakdown size & forecasts, 2022-2032
10.5.2.3. Source breakdown size & forecasts, 2022-2032
10.5.2.4. Disease Areas breakdown size & forecasts, 2022-2032
10.5.2.5. End User breakdown size & forecasts, 2022-2032
10.5.3. Rest of Middle East & Africa Antibody Therapeutics Market
10.5.3.1. Format breakdown size & forecasts, 2022-2032
10.5.3.2. Route of Administration breakdown size & forecasts, 2022-2032
10.5.3.3. Source breakdown size & forecasts, 2022-2032
10.5.3.4. Disease Areas breakdown size & forecasts, 2022-2032
10.5.3.5. End User breakdown size & forecasts, 2022-2032
Chapter 11. Competitive Intelligence
11.1. Key Company SWOT Analysis
11.1.1. AbbVie Inc.
11.1.2. AbCellera Biologics Inc.
11.1.3. Adaptimmune Therapeutics PLC.
11.2. Top Market Strategies
11.3. Company Profiles
11.3.1. AbbVie Inc.
11.3.1.1. Key Information
11.3.1.2. Overview
11.3.1.3. Financial (Subject to Data Availability)
11.3.1.4. Product Summary
11.3.1.5. Market Strategies
11.3.2. AbCellera Biologics Inc.
11.3.3. Adaptimmune Therapeutics PLC.
11.3.4. ADC Therapeutics SA
11.3.5. Aenova Holding GmbH
11.3.6. Almac Group Limited
11.3.7. Amgen Inc.
11.3.8. Antikor Biopharma
11.3.9. Argenx SE
11.3.10. Astellas Pharma Inc.
11.3.11. AstraZeneca PLC
11.3.12. Baxter International Inc.
11.3.13. Bayer AG
11.3.14. Becton, Dickinson and Company
11.3.15. Bio-Rad Laboratories, Inc.
Chapter 12. Research Process
12.1. Research Process
12.1.1. Data Mining
12.1.2. Analysis
12.1.3. Market Estimation
12.1.4. Validation
12.1.5. Publishing
12.2. Research Attributes

OUR CLIENTS

500 N Michigan Ave, Suite 600, Chicago, Illinois 60611, UNITED STATES
+18882123539
sales@reportocean.com